Mestag was founded in 2020 by leading investigators and SV Health Investors to develop new medicines for people affected by inflammatory disease and cancer. Our goal is to bring transformative therapies to patients by targeting activated fibroblast populations and their role in influencing the immune system in disease. The founding investigators comprise leading experts in inflammatory disease, cancer, computational biology and fibroblast biology from world-leading institutes in the US and UK including University of Oxford, Harvard Medical School, the Broad Institute, Cold Spring Harbor and Brigham and Women’s Hospital. We are progressing a pipeline of first-in-class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and immuno-oncology and are supported by leading global investors SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (formerly Google Ventures) and Northpond Ventures. The company is based in Cambridge, UK. We are actively assembling a driven, motivated team to discover and develop new therapeutics. We are hiring! Reach out to learn more about opportunities to join our team.